Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Colla...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: September 25, 2023

Statement by the Prime Minister on Yom Kippur • Intel Editorial: Intel Addresses Semiconductor Workforce Shortage • 2023 GLOBAL CITIZEN FESTIVAL SEES $240 MILLION COMMITMENT FROM FRANCE AND NORWAY TO COMBAT THE GLOBAL FOOD CRISIS • Statement by Minister Khera on Yom Kippur • 65+ Populations in Upstate NY's 4 Largest Regions Surging, Getting Poorer; AARP NY to Meet with Local Leaders • A Meyers Manx Collaboration with Artist Sage Vaughn Contributes $200,000 to Arts Education Fundraiser • Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo • THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON • Student Entrepreneurs from Yale University Win Prestigious $1 Million 2023 Hult Prize • Reactive Technologies’ Grid Inertia Measurement Tech to Enable Offshore Wind Rollout in Taiwan • Sixth Annual War Heroes on Water Charity Sportfishing Tournament Kicks Off, Bringing Hope and Healing to Combat-Wounded Veterans • Joint Statement on the Importance of Comprehensive, Multidisciplinary and Collaborative Care for Patients with Peripheral Artery • Guidewire Optimistic About New Direction of California Insurance • Shift4 Partners with Give Lively to Offer Powerful Fundraising Solution to Nonprofits • Unitedprint.com collaborates with Pexels.com • 2023 Gangnam Festival to be Held in Gangnam, the Heart of K-pop • Wondershare FamiSafe 7.0 safeguarding Children with AI • No more oil, gas and coal. Two nation-states join growing bloc of countries calling for a Fossil Fuel Non-Proliferation Treaty • France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival • PRAIRIE VIEW A&M UNIVERSITY ANNOUNCES 2023-2024 WRITER-IN-RESIDENCE ATTICA LOCKE

Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Developme

CHICAGO , June 04 /Businesswire/ - Nucleai, a leading provider of artificial intelligence (AI) solutions for pathology and spatial biology, and Mayo Clinic BioPharma Diagnostics are pleased to announce a strategic collaboration to bring world-class digital pathology solutions, technologies, and services to support drug development and clinical practice. This collaboration combines Nucleai’s AI-powered spatial biology technology with Mayo’s longitudinally annotated, multi-modal data sets, world-class lab services, and clinical diagnostic footprint.

"We are excited to work closely with Mayo to bring spatial biology to the hands of the biopharma industry, clinicians and researchers,” said Avi Veidman, CEO of Nucleai. "By combining Mayo Clinic's extensive multi-modal datasets, laboratories, and clinical expertise with Nucleai's advanced AI platform, we can bring scale and impact to the entire precision medicine landscape.”

Through this collaboration, Nucleai and Mayo Clinic will focus on several distinct offerings to support drug development including biomarker discovery and validation, end-to-end spatial biology testing and algorithm deployment for clinical trials and diagnostic use.

About Nucleai:

Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data. Nucleai provides pharmaceutical companies, contract research organizations, and diagnostics laboratories with a state-of-the-art AI platform to improve clinical trials and clinical decision-making. For more information, please visit www.nucleai.ai.